CAR-T therapy in myeloma and lymphoma

CAR-T therapy has revolutionized the treatment landscape of several hematological malignancies, and ongoing clinical trials continue to provide valuable data on the safety and efficacy of these agents. At the 4th International Workshop on CAR-T (iwCAR-T) meeting held in Tampa, FL, several fascinating sessions took place, where leading experts discussed the application and challenges of CAR-T therapy in hematological malignancies, including lymphoma and multiple myeloma. 

In this exclusive podcast, Yi Lin, MD, PhD, Mayo Clinic, Rochester, MN, Suzanne Trudel, MD, MSc, Princess Margaret Cancer Centre, Toronto, Canada, Frederick Locke, MD, H. Lee Moffitt Cancer Center, Tampa, FL, and Krina Patel, MD, MSc, The University of Texas MD Anderson Cancer Center, Houston, TX, share key updates from the lymphoma and myeloma sessions held at this year’s meeting. The experts discuss several topics, including the benefit of CAR-T in second-line diffuse large B-cell lymphoma (DLBCL), strategies to overcome the challenges of CAR-T therapy in myeloma, patient selection for CAR-T therapy, and more.